Last 24.00 GBp
Change Today +1.75 / 7.87%
Volume 236.1K
AGY On Other Exchanges
As of 11:30 AM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

allergy therapeutics plc (AGY) Snapshot

23.00 GBp
Previous Close
22.25 GBp
Day High
25.00 GBp
Day Low
23.00 GBp
52 Week High
03/7/14 - 32.75 GBp
52 Week Low
11/26/13 - 7.25 GBp
Market Cap
Average Volume 10 Days
0.0012 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

allergy therapeutics plc (AGY) Related Businessweek News

No Related Businessweek News Found

allergy therapeutics plc (AGY) Details

Allergy Therapeutics plc, a specialty pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical vaccine products for the immunological treatment of allergic conditions primarily in Europe. The company’s primary flagship product consists of the Pollinex Quattro for the treatment of allergic conditions; and monophosphoryl-lipid A, a substance, which enhances the immune response to an antigen or allergen. It offers sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; probiotic products, such as Kallergen-Th, ATI Prob, and Pollagen; Acarovac Plus, a novel tyrosine-adsorbed, modified-allergen product developed for treatment of perennial mite allergy; and DAP, a product for use in the diagnosis of type I or immediate hypersensitivity to benzylpenicillin and related antibiotics (betalactams) by means of cutaneous tests (prick and intradermal). The company markets its products under various brands, including Pollinex Quattro, Polligoid, and TA Gräser Top. Allergy Therapeutics plc was founded in 1934 and is headquartered in Worthing, the United Kingdom.

345 Employees
Last Reported Date: 09/24/14
Founded in 1934

allergy therapeutics plc (AGY) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 291.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 192.8K GBP
Compensation as of Fiscal Year 2014.

allergy therapeutics plc (AGY) Key Developments

Allergy Therapeutics Appoints Jean-Yves Pavée as a Non-Executive Director

Allergy Therapeutics has appointed, with immediate effect, Jean-Yves Pavée as a Non-Executive Director. Jean-Yves Pavée is Senior Vice President, Developed Markets for Abbott's Established Products Division. He was appointed to his role in July 2013. Previously, he served as Divisional Vice President, EMEA East, and Division Vice President, Pharmaceuticals, Europe South. He joined Abbott in 1992.

Allergy Therapeutics Announces Appointment of Daphne Tsitoura as Head of Clinical Science, Effective November 10, 2014

Allergy Therapeutics announced the appointment of Daphne Tsitoura as head of Clinical Science the Clinical Development team in Munich and Worthing from the 10th November 2014, reporting to Professor Tim Higgenbottam. Tsitoura joins Allergy Therapeutics from GSK, where she has spent the last eight years as principal physician in the respiratory therapeutic area in the GSKs' Stevenage research centre UK and has maintained a clinical link with allergy as an associate Allergist at University College Hospital London UK.

Allergy Therapeutics plc Announces Alejandro Esteban Weinstein Manieu Steps Down from the Board

Allergy Therapeutics plc announced that Alejandro Esteban Weinstein Manieu has stepped down from the Board with immediate effect.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGY:LN 24.00 GBp +1.75

AGY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALK-Abello A/S kr697.00 DKK -2.00
DBV Technologies SA €40.80 EUR +0.64
Merck & Co Inc $59.66 USD +0.28
Sanofi €75.91 EUR +0.89
Stallergenes SA €49.99 EUR +0.47
View Industry Companies

Industry Analysis


Industry Average

Valuation AGY Industry Range
Price/Earnings 100.0x
Price/Sales 2.6x
Price/Book 6.0x
Price/Cash Flow 121.6x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGY THERAPEUTICS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at